Literature DB >> 3556336

Cellular hypersensitivity to gluten derived peptides in coeliac disease.

R Guan, P M Rawcliffe, J D Priddle, D P Jewell.   

Abstract

Wheat gluten derived antigens have been tested for their ability to inhibit the migration of leucocytes from healthy subjects and patients with coeliac disease. Three preparations of a water soluble fraction (Frazer's fraction III, FIII) of partial peptic tryptic digests of wheat gluten had different effects in a direct (one stage) assay. Subfractions B and B2 caused migration inhibition of leucocytes from patients with treated coeliac disease but not of leucocytes from healthy volunteers or patients with Crohn's disease or ulcerative colitis. This migration inhibition seems to be specific for gluten fractions because maize zein fraction B, beta-lactoglobulin and ovalbumin did not cause it. The sensitivity of coeliac leucocytes to fraction B is not related to factors present in coeliac serum as the migration of leucocytes from healthy individuals preincubated with coeliac sera was not inhibited. Puromycin diminished inhibition by fraction B, which was active at 1.2 micrograms/ml in an indirect (two stage) migration inhibition assay; this is consistent with a process involving elaboration of lymphokine(s). More highly purified fractions of B2, P1-P4 were prepared by reverse phase high performance liquid chromatography (HPLC) and showed differing potency in direct and indirect assays, with P4 being the most active fraction. Inhibition of migration by gluten derived peptides appears to result from the release of lymphokine by leucocytes specifically from coeliac patients.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3556336      PMCID: PMC1432825          DOI: 10.1136/gut.28.4.426

Source DB:  PubMed          Journal:  Gut        ISSN: 0017-5749            Impact factor:   23.059


  10 in total

1.  Gluten-induced enteropathy: the effect of partially digested gluten.

Authors:  A C FRAZER; R F FLETCHER; C A ROSS; B SHAW; H G SAMMONS; R SCHNEIDER
Journal:  Lancet       Date:  1959-09-05       Impact factor: 79.321

2.  Identifying toxic fractions of wheat gluten and their effect on the jejunal mucosa in coeliac disease.

Authors:  A S Dissanayake; D W Jerrome; R E Offord; S C Truelove; R Whitehead
Journal:  Gut       Date:  1974-12       Impact factor: 23.059

3.  Leukocyte migration agarose technique: some technical details.

Authors:  J E Clausen
Journal:  Acta Allergol       Date:  1973-12

4.  [Gliadin-induced migration inhibition of peripheral leucocytes by the agarose-plate technique in patients with coeliac disease (author's transl)].

Authors:  F R Douwes; I Lippmann-Nielsen; R Hanke
Journal:  Dtsch Med Wochenschr       Date:  1977-05-13       Impact factor: 0.628

5.  The specificity of wheat protein reactivity in coeliac disease.

Authors:  C O'Farrelly; W T Hekkens; C Feighery; D G Weir
Journal:  Scand J Gastroenterol       Date:  1983-07       Impact factor: 2.423

6.  Specificity of leucocyte migration inhibition test in coeliac disease. A reassessment using different gluten subfractions.

Authors:  G R Corazza; P M Rawcliffe; M Frisoni; P Sarchielli; M Londei; M Campieri; R Lazzari; G Gasbarrini
Journal:  Clin Exp Immunol       Date:  1985-04       Impact factor: 4.330

7.  Cellular response to alpha-gliadin in untreated coeliac disease.

Authors:  C O'Farrelly; C Feighery; J F Greally; D G Weir
Journal:  Gut       Date:  1982-01       Impact factor: 23.059

8.  Antigenic reactivity of peptides derived from wheat gluten with sera from patients with coeliac disease.

Authors:  P M Rawcliffe; J D Priddle; D P Jewell
Journal:  Clin Sci (Lond)       Date:  1985-07       Impact factor: 6.124

9.  Leucocyte migration inhibition test in coeliac disease - a reappraisal.

Authors:  F G Simpson; H P Field; P D Howdle; D A Robertson; M S Losowsky
Journal:  Gut       Date:  1983-04       Impact factor: 23.059

10.  Immunological assay for the diagnosis of coeliac disease: interaction between purified gluten fractions.

Authors:  A Ashkenazi; S Levin; D Idar; A Or; I Rosenberg; Z T Handzel
Journal:  Pediatr Res       Date:  1980-05       Impact factor: 3.756

  10 in total
  3 in total

1.  Macrophage procoagulant activity as an assay of cellular hypersensitivity to gluten peptides in coeliac disease.

Authors:  J M Devery; C L Geczy; D DeClarle; J H Skerritt; S A Krillis
Journal:  Clin Exp Immunol       Date:  1990-11       Impact factor: 4.330

2.  Natural killer cell activity in coeliac disease: effect of in vitro treatment on effector lymphocytes and/or target lymphoblastoid, myeloid and epithelial cell lines with gliadin.

Authors:  M A Castany; H H Nguyen; M Pospísil; P Fric; H Tlaskalová-Hogenová
Journal:  Folia Microbiol (Praha)       Date:  1995       Impact factor: 2.099

3.  Cellular hypersensitivity to a synthetic dodecapeptide derived from human adenovirus 12 which resembles a sequence of A-gliadin in patients with coeliac disease.

Authors:  G J Mantzaris; J A Karagiannis; J D Priddle; D P Jewell
Journal:  Gut       Date:  1990-06       Impact factor: 23.059

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.